Trade Q32 Bio Inc - QTTB CFD

Add to favourite

43.3271

5.49%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

1.2158

Long position overnight fee

-0.026235%

Short position overnight fee

0.004012%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	45.1671
Open	45.1271
1-Year Change	3800.02%
Day's Range	41.3471 - 45.1271

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Sep 13, 2024	45.1671	-0.1600	-0.35%	45.3271	47.3371	43.3571
Sep 12, 2024	44.6771	-3.5300	-7.32%	48.2071	49.2171	42.0871
Mar 25, 2024	0.9171	0.0199	2.22%	0.8972	0.9695	0.8971
Mar 22, 2024	0.8981	0.0294	3.38%	0.8687	0.9321	0.8537
Mar 21, 2024	0.8819	0.0138	1.59%	0.8681	0.8922	0.8671
Mar 20, 2024	0.8931	0.0145	1.65%	0.8786	0.9170	0.8571
Mar 19, 2024	0.8973	-0.0098	-1.08%	0.9071	0.9322	0.8783
Mar 18, 2024	0.8973	0.0002	0.02%	0.8971	0.9021	0.8651
Mar 15, 2024	0.9171	0.0000	0.00%	0.9171	0.9251	0.9071
Mar 14, 2024	0.9171	0.0100	1.10%	0.9071	0.9501	0.9071
Mar 13, 2024	0.9071	0.0300	3.42%	0.8771	0.9071	0.8771
Mar 12, 2024	0.8946	0.0175	2.00%	0.8771	0.8971	0.8771
Mar 11, 2024	0.9069	0.0298	3.40%	0.8771	0.9069	0.8771
Mar 8, 2024	0.8869	-0.0003	-0.03%	0.8872	0.8981	0.8771
Mar 7, 2024	0.8995	-0.0070	-0.77%	0.9065	0.9071	0.8471
Mar 6, 2024	0.8971	0.0300	3.46%	0.8671	0.8971	0.8671
Mar 5, 2024	0.8669	-0.0102	-1.16%	0.8771	0.8874	0.8585
Mar 4, 2024	0.8917	-0.0083	-0.92%	0.9000	0.9000	0.8640
Mar 1, 2024	0.8931	-0.0369	-3.97%	0.9300	0.9400	0.8800
Feb 29, 2024	0.9200	0.0189	2.10%	0.9011	0.9300	0.8828

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Homology Medicines Company profile

About Homology Medicines Inc

Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. Its various set of AAVHSCs allows it to target, via a single injection, a range of disease-relevant tissues, including the liver, central nervous system (CNS), peripheral nervous system (PNS), bone marrow, muscle and eye. Its lead product candidate, HMI-102, is a gene therapy for the treatment of adults with phenylketonuria (PKU). Its other gene therapy product development candidates for the treatment of lysosomal storage diseases are HMI-203, for the treatment of mucopolysaccharidosis type II (MPS II) and HMI-202.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Homology Medicines Inc revenues increased from $1.7M to $33.2M. Net loss decreased 37% to $62.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $63.1M (expense), General and administrative - Balancing decrease of 1% to $19.8M (expense).

Industry:

Bio Therapeutic Drugs

1 Patriots Park
BEDFORD
MASSACHUSETTS 01730-2343
US

News

FOMC Decision Preview

As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.

09:48, 16 September 2024

ECB Preview: cuts expected but the pace is uncertain

Markets expect the ECB to cut rates again in September, but how many more?

12:34, 11 September 2024

Market analysis: US CPI and PPI

Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.

07:56, 10 September 2024

Introducing Newsquawk: your new in-platform newsfeed

We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.

14:09, 20 August 2024